Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics.
作者信息
Wong Alissa K, Mooghali Maryam, Ramachandran Reshma, Ross Joseph S, Wallach Joshua D
机构信息
Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut.
出版信息
JAMA Netw Open. 2023 Aug 1;6(8):e2331753. doi: 10.1001/jamanetworkopen.2023.31753.
Abstract
摘要
相似文献
1
Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics.
JAMA Netw Open. 2023 Aug 1;6(8):e2331753. doi: 10.1001/jamanetworkopen.2023.31753.
2
Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
JAMA Netw Open. 2022 Nov 1;5(11):e2239336. doi: 10.1001/jamanetworkopen.2022.39336.
3
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
BMJ. 2015 Sep 23;351:h4633. doi: 10.1136/bmj.h4633.
4
Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
JAMA. 2017 May 9;317(18):1854-1863. doi: 10.1001/jama.2017.5150.
5
The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
J Manag Care Spec Pharm. 2023 May;29(5):464-471. doi: 10.18553/jmcp.2023.22415. Epub 2023 Mar 29.
6
Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
Ther Innov Regul Sci. 2019 Nov;53(6):752-758. doi: 10.1177/2168479018812058. Epub 2018 Dec 3.
7
FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
JAMA. 2020 Jan 14;323(2):164-176. doi: 10.1001/jama.2019.20288.
8
Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
Clin Ther. 2013 Jun;35(6):808-18. doi: 10.1016/j.clinthera.2013.04.004. Epub 2013 May 28.
9
US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018.
Clin Trials. 2021 Aug;18(4):488-499. doi: 10.1177/17407745211005044. Epub 2021 Apr 16.
10
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
BMJ. 2020 Oct 7;371:m3434. doi: 10.1136/bmj.m3434.
引用本文的文献
1
Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines.
JAMA. 2025 Sep 3. doi: 10.1001/jama.2025.13917.
2
Current landscape of innovative drug development and regulatory support in China.
Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.
3
Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies.
JAMA Netw Open. 2024 Aug 1;7(8):e2430486. doi: 10.1001/jamanetworkopen.2024.30486.
4
Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics.
JAMA. 2023 Dec 26;330(24):2392-2394. doi: 10.1001/jama.2023.21958.
本文引用的文献
1
Clinical development times for innovative drugs.
Nat Rev Drug Discov. 2022 Nov;21(11):793-794. doi: 10.1038/d41573-021-00190-9.
2
Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
JAMA Netw Open. 2020 Apr 1;3(4):e203284. doi: 10.1001/jamanetworkopen.2020.3284.
3
Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
J Gen Intern Med. 2019 Apr;34(4):492-495. doi: 10.1007/s11606-018-4779-x.
4
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031.
5
The FDA's Expedited Programs and Clinical Development Times for Novel Therapeutics, 2012-2016.
JAMA. 2017 Dec 5;318(21):2137-2138. doi: 10.1001/jama.2017.14896.
Zotero 插件